[HTML][HTML] Hepatitis B blood donor screening data: An under-recognized resource for Canadian public health surveillance
Hepatitis B surveillance is essential to achieving Canada's goal of eliminating hepatitis B by
2030. Hepatitis B rates, association of infection with vaccine age-eligibility, and risk factors …
2030. Hepatitis B rates, association of infection with vaccine age-eligibility, and risk factors …
Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network
CS Coffin, A Ramji, CL Cooper, D Miles… - … Open Access Journal, 2019 - cmajopen.ca
Background: Published Canadian epidemiologic data on hepatitis B virus (HBV) infection
include single-centre studies or are focused on Indigenous populations. We performed a …
include single-centre studies or are focused on Indigenous populations. We performed a …
[HTML][HTML] Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos (t) ide analogue
A Ramji, K Doucette, C Cooper, GY Minuk… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Hepatitis B virus (HBV) nucleos (t) ide analog (NA) therapy reduces liver
disease but requires prolonged therapy to achieve hepatitis B surface antigen (HBsAg) loss …
disease but requires prolonged therapy to achieve hepatitis B surface antigen (HBsAg) loss …
[PDF][PDF] Chronic hepatitis B in British Columbia.
PHP Wong - British Columbia Medical Journal, 2022 - bcmj.org
Chronic hepatitis B is caused by the hepatitis B virus, a member of the Hepadnaviridae
family. It is a common infection with a worldwide prevalence of more than 250 million …
family. It is a common infection with a worldwide prevalence of more than 250 million …
Real-world tertiary referral centre experience stopping nucleos (t) ide analogue therapy in patients with chronic hepatitis B
BACKGROUND: Identifying strategies for stopping nucleos (t) ide analogues (NUC) in
patients with chronic hepatitis B (CHB) is a major goal in CHB management. Our study …
patients with chronic hepatitis B (CHB) is a major goal in CHB management. Our study …
Medicare Part D Spending for Hepatitis B Virus Drugs: Completing the Picture and Extending the Dataset
analyzing spending for oral drugs used to treat hepatitis B in Medicare Part D between 2013
and 2020. The analysis included the originator and generic forms for tenofovir disoproxil …
and 2020. The analysis included the originator and generic forms for tenofovir disoproxil …
A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B
Abstract Background: Pegylated interferon (Peg-IFN) is recommended as first-line therapy
for chronic hepatitis B (CHB) but has significant side effects and is rarely used compared to …
for chronic hepatitis B (CHB) but has significant side effects and is rarely used compared to …
[PDF][PDF] Burden of Chronic Hepatitis B in Alberta, Canada
GS Kochaksaraei - 2023 - prism.ucalgary.ca
Burden of Chronic Hepatitis B in Alberta, Canada Page 1 University of Calgary PRISM
Repository https://prism.ucalgary.ca The Vault Open Theses and Dissertations 2023-10-12 …
Repository https://prism.ucalgary.ca The Vault Open Theses and Dissertations 2023-10-12 …
[HTML][HTML] Causes and Outcomes of Medicolegal Proceedings Following Gastrointestinal Endoscopy in Canada
Background and Aims Endoscopic procedures are frequently performed in Canada but can
be associated with potential complications and medicolegal implications. This study aimed …
be associated with potential complications and medicolegal implications. This study aimed …
Exception points for liver transplantation: A Canadian review
SE Congly, V Marquez, RA Bhanji… - Canadian Liver …, 2022 - canlivj.utpjournals.press
Background: Exception points for liver transplant (LT) allocation are used to account for
mortality risk not reflected by scoring systems such as the Model for End-Stage Liver …
mortality risk not reflected by scoring systems such as the Model for End-Stage Liver …